Human IL-12 / IL-23 Monoclonal Antibody

Briakinumab is a human anti-IL-12 / IL-23 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. Synonyma: CLMF, NKSF, CLMF2, IMD28, IMD29, NKSF2, IL-12B/P19, SGRF, IL-23, IL-23A, IL23P19